The resale registration is small relative to float and does not represent a primary offering. Monitor for any clinical data readouts from the APTN-101 Phase I trial and for the company's ability to raise additional capital given the going-concern warning. The $5.00 warrant exercise price is below the current $6.27 market price, creating potential modest cash inflow if exercised.
Executive Summary
Adaptin Bio filed an S-1 registration statement to register 382,400 shares of common stock and 38,240 shares underlying placement agent warrants for resale by selling stockholders. The company is a pre-revenue biotech developing APTN-101 (BRiTE platform) for glioblastoma, with a going-concern warning from its auditor and no commercial revenue. This is a routine resale registration that does not raise new capital for the company (except potential cash from warrant exercises).
Key Facts
- Registers 382,400 shares of common stock and 38,240 shares underlying placement agent warrants for resale by selling stockholders
- Placement agent warrants have a $5.00 exercise price and 5-year term
- Company has generated no revenue from commercial sales and has a going-concern warning from its auditor
- Lead candidate APTN-101 (EGFRvIII-targeted BRiTE) is in a Phase I investigator-initiated trial for glioblastoma, opened for enrollment at Duke University in August 2026
- 9,244,937 shares of common stock outstanding as of August 25, 2026; stock trades on OTCQB at $6.27 per share
- Company emerged from a merger with Unite Acquisition 1 Corp. in February 2025
Financial Impact
Resale registration covers ~4.5% of outstanding shares (420,640 shares vs 9.24M outstanding). No new capital raised for the company except potential cash from warrant exercises at $5.00/share.
Risk Factors
- Going-concern uncertainty; company needs substantial additional capital to continue operations
- APTN-101 is in very early-stage clinical development with no guarantee of success
- Resale by selling stockholders could create modest selling pressure
- Limited access to capital markets as a development-stage biotech on OTCQB
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001213900-26-095034 |
| Document: 0001213900-26-095034-index.html | 0001213900-26-095034 |
| Document: 0001213900-26-095034.txt | 0001213900-26-095034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | EFFECT | — | awaiting T+20 | — | — |
Aug 28, 2026 8w ago | S-1 | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers